Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Title A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients with Advanced Cancers
Contact FS
Principal Investigator Alex Adjei, MD PhD
Study Number 196111
Phase1
Summary The purpose of the study is to find the tolerable dose of an investigational drug CBLB502 that can be given to patients with cancer without causing severe side effects.  Also, to find out the effectiveness of CBLB502 in advanced cancers.
Eligibility
  •  Please see Clinical trials.gov listing for eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov
Source URL (retrieved on 05/23/2013 - 10:27pm): http://www.roswellpark.org/clinical-trials/list/196111-0